High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma

Wu, Tsung Teh; Lohse, Christine M.; Zhang, Lizhi

doi:10.1016/j.humpath.2014.04.026

Cited by 20 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then 16 papers were excluded because of no available data or non English papers. Eventually, 23 articles were enrolled ( Motoyama et al, 2008 ; Wang et al, 2011 ; Yang et al, 2011 ; Wu et al, 2012 ; Rizzi et al, 2013 ; Yamazaki et al, 2013 ; Califano et al, 2014 ; Kong et al, 2014 ; Lee et al, 2014 , 2015 ; Jun et al, 2015 ; Kim et al, 2015 ; Liu et al, 2015 ; Xia et al, 2015b ; Na et al, 2016 ; Wei et al, 2016 ; Wu J. et al, 2016 ; Zhang et al, 2016 ; Zhao et al, 2016 ; Fang et al, 2017 ; Gunther et al, 2017 ; Mito et al, 2017 ; Strell et al, 2017 ). In total, 15 types of cancers were included in this meta-analysis including ampullary adenocarcinoma, breast cancer, colorectal cancer, clear cell renal cell carcinoma (ccRCC), esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinomas, nasopharyngeal carcinoma, ovarian carcinoma, oral squamous cell carcinoma, pancreatic ductal adenocarcinoma, and tongue squamous cell carcinoma.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets

Huang

Yang²,

Cheng

et al. 2018

Front. Physiol.

View full text Add to dashboard Cite

Background: Emerging evidences have shown that the high-mobility group protein A2 (HMGA2) can aberrantly express in human cancers, and it could be an unfavorable prognostic factor in cancer patients. However, the prognostic value of HMGA2 was still unclear. Therefore, in this study, we explored the potential prognostic value of HMGA2 in human cancers by using meta-analysis based on published literatures and The Cancer Genome Atlas (TCGA) datasets.Methods: Through searching PubMed, Embase, Web of Science and Cochrane Library databases, we were able to identify the studies evaluating the prognostic value of HMGA2 in cancers. Then, UALCAN and TCGA datasets were used to validate the results of our meta-analysis.Results: In all, 15 types of cancers were included in this meta-analysis. Pooled results showed that high level of HMGA2 was significantly correlated with poor OS (HR = 1.88, 95% confidence interval (CI) = 1.68-2.11, P < 0.001) and poor DFS (HR = 2.49, 95% CI = 1.44-4.28, P = 0.001) in cancer patients. However, subgroup analyses revealed that the high expressed HMGA2 was associated with poor OS in head and neck cancer, gastric cancer and colorectal cancer, but not esophageal cancer and ovarian cancer. Based on TCGA datasets, we analyzed 9944 patients with 33 types of cancers. Significant association between HMGA2 overexpression and poor OS was found in 14 types of cancers. Taken together, consistent results were observed in clear cell renal cell carcinoma, esophageal adenocarcinoma, head and neck cancer, hepatocellular carcinoma, ovarian carcinoma, and pancreatic ductal adenocarcinoma.Conclusion: Our meta-analysis showed the significance of HMGA2 and its prognostic value in various cancers. High level of HMGA2 could be associated with poor OS in patients with clear cell renal cell carcinoma, head and neck cancer, hepatocellular carcinoma and pancreatic ductal adenocarcinoma, but not esophageal adenocarcinoma and ovarian carcinoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets

Huang

Yang²,

Cheng

et al. 2018

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…HMGA2 serves a key role in the process of embryogenesis, however, it becomes an oncoprotein when expressed in adult cells. HMGA2 is highly expressed in a various types of human cancer and serves as a prognostic marker (15,40,41,133,135,145,(159)(160)(161)(162)(163)(164)(165)(166)(167)(168)(169)(170)(171)(172)(173)(174)(175)(176)(177) (Table I). Almost a decade ago, Fusco and Fedele reviewed the functions of HMGA proteins, including HMGA1 and HMGA2, in human neoplastic diseases, and suggested that the detection of HMGA be introduced as a routine procedure in clinical tumour analysis (7).…”

Section: Considerations and Perspectivesmentioning

confidence: 99%

Oncological role of HMGA2 (Review)

2019

View full text Add to dashboard Cite

The high mobility group A2 (HMGA2) protein is a non-histone architectural transcription factor that modulates the transcription of several genes by binding to AT-rich sequences in the minor groove of B-form DNA and alters the chromatin structure. As a result, HMGA2 influences a variety of biological processes, including the cell cycle process, DNA damage repair process, apoptosis, senescence, epithelial-mesenchymal transition and telomere restoration. In addition, the overexpression of HMGA2 is a feature of malignancy, and its elevated expression in human cancer predicts the efficacy of certain chemotherapeutic agents. Accumulating evidence has suggested that the detection of HMGA2 can be used as a routine procedure in clinical tumour analysis. Contents 1. Introduction 2. Regulation of the expression of HMGA2 3. Expression of HMGA2 in cancer 4. HMGA2 influences the cell cycle of cancer cells 5. HMGA2 and the DNA damage response 6. Dual role of HMGA2 in the regulation of non-homologous end-joining 7. HMGA2 promotes base excision repair 8. HMGA2 promotes nucleotide excision repair 9. Apoptosis 10. Dual role of HMGA2 in apoptosis 11. HMGA2 impairs or enhances cellular senescence 12. HMGA2 promotes epithelial-mesenchymal transition 13. HMGA2 maintains telomere length 14. HMGA2 predicts the efficacy of chemotherapy 15. Considerations and perspectives Hangzhou, Zhejiang 310014;

show abstract

“…HMGA2 can regulate the expression of both oncogenes and tumor suppressors [9]. HMGA2 is important during embryonic morphogenesis [10] and is aberrantly expressed in cancer [7, 10-32]. High levels of HMGA2 in cancer are associated with increased invasiveness, stemness and poor prognosis [12, 14, 18, 22, 24-36] However, the functional importance of HMGA2 in regulating stemness and tumorigenicity in GBM are poorly understood.…”

Section: Introductionmentioning

confidence: 99%

The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma

et al. 2016

View full text Add to dashboard Cite

Glioblastoma (GBM) contains a population of stem-like cells that promote tumor invasion and resistance to therapy. Identifying and targeting stem cell factors in GBM may lead to the development of more effective therapies. High Mobility Group AT-hook 2 (HMGA2) is a transcriptional modulator that mediates motility and self-renewal in normal and cancer stem cells. We identified increased expression of HMGA2 in the majority of primary human GBM tumors and cell lines compared to normal brain. Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells. Targeting HMGA2 with lentiviral short hairpin RNA (shRNA) led to decreased GBM stemness, invasion, and tumorigenicity. Ectopic expression of HMGA2 in GBM cell lines promoted stemness, invasion, and tumorigenicity. Our data suggests that targeting HMGA2 in GBM may be therapeutically beneficial.

show abstract

High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma

Cited by 20 publications

References 38 publications

Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets

Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets

Oncological role of HMGA2 (Review)

The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma

Contact Info

Product

Resources

About